Krebs Simone, Baird Lisa, Pirovano Giacomo, Yamaguchi Aiko, Coll Ryan P, Lee Jason T, Carroll Laurence S, Pomper Martin G, Manning H Charles
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
Mol Imaging Biol. 2025 Sep 19. doi: 10.1007/s11307-025-02054-9.
Theranostics, a concept combining "therapy" and "diagnostics", is poised to enter an exponential growth phase. By using specific diagnostic markers to guide the selection and application of targeted treatments directed at those markers, this approach aims to improve effectiveness and reduce unnecessary interventions. While several agents have been approved by the FDA recently, multiple additional theranostics are being developed, studied in clinical trials and expected to enter clinical practice in short order. As part of the "Translation of New Therapy (TNT) Interest Group's Radiotheranostics Kick-off" pre-meeting of the annual World Molecular Imaging Conference (WMIC) 2024 over 350 attendees with 10% leaders from industry, 60% senior and junior investigators in academia and 30% trainees discussed the key challenges and opportunities in implementing a theranostic research program in academia, which are addressed in this white paper. Overarching themes included funding, regulatory hurdles, and workforce training. Panel recommendations included leveraging existing expertise and patient populations, securing revenue streams, exploring alternative funding sources, and developing a multifaceted approach to promote training, education and public awareness, including fostering academic-industry partnerships. By shedding light on the gap between research and real-world program implementation, this white paper and forthcoming pre-meetings at WMIC aim to define a practical framework for building successful programs based on insights from recent research.
治疗诊断学，一个将“治疗”与“诊断”相结合的概念，正准备进入指数增长阶段。通过使用特定的诊断标志物来指导针对这些标志物的靶向治疗的选择和应用，这种方法旨在提高疗效并减少不必要的干预措施。虽然最近有几种药物已获得美国食品药品监督管理局（FDA）的批准，但还有多种其他治疗诊断剂正在研发中，正在进行临床试验研究，并有望很快进入临床实践。作为2024年年度世界分子成像大会（WMIC）“新疗法转化（TNT）兴趣小组的放射治疗诊断学启动”会前会议的一部分，超过350名与会者，其中10%来自行业的领导者、60%学术界的资深和初级研究人员以及30%的学员，讨论了在学术界实施治疗诊断学研究项目的关键挑战和机遇，本白皮书对此进行了阐述。总体主题包括资金、监管障碍和劳动力培训。小组建议包括利用现有专业知识和患者群体、确保收入来源、探索替代资金来源，以及制定多方面的方法来促进培训、教育和公众意识，包括促进学术 - 产业伙伴关系。通过揭示研究与实际项目实施之间的差距，本白皮书以及即将在WMIC举行的会前会议旨在根据近期研究的见解定义一个构建成功项目的实用框架。
